Explore tweets tagged as #PDL1
Durvalumab (+FLOT) is now @US_FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN! We 🗣️ this trial, findings, PDL1, and AEs w/ @YJanjigianMD Full 🗣️: ⭐️ https://t.co/Q53ZeQWxeG ⭐️ Also on “Oncology Brothers” podcast @OncoAlert @OncUpdates #gism
1
14
24
From being the first national lab chain to launch Claudin 18.2 in India and our first positive case, then representing India at the APAC meeting for precision oncology for markers including Claudin 18.2, FGFR 2b and TAP scoring for PDL1 at Seoul- South Korea, to completing
0
0
1
#ESMO25 Dr. Richard Gralla presents TeLuRide-005: phase II study of first-line EIK1001 (TLR7/8 dual agonist) with pembrolizumab + chemo in advanced NSCLC. Phase I studies showed safety, some responses in heavily pretreated NSCLC. Potential PDL1 synergy? #ESMOAmbassadors
2
8
20
Prior anti-PD1/pdl1 does not compromise responses to nivolumab plus ipilumumab. Results from DART (NCI/SWOG): largest immunotherapy rare cancer trial 🎯🎯 https://t.co/wEeHPL5OYI
3
3
21
Matterhorn Final OS CURVES. Look at CI for PDL1 less than 1 %. I will prefer to use it in PDL1 positive pts . What about you ? For all comers? @dr_yakupergun @Erman_Akkus @GIMedOnc @aparna1024 @myESMO @OncoAlert #esmo2025 @MyriamChalabi
9
11
29
Prof. Gordon J. Freeman shares his insights on how to optimize PD1/PDL1 treatment at SITC25. Link in the comments. 👇 @sitcancer
1
1
4
ASCENT-03 support sacituzumab govitecan (SG) as a potential new standard for previously untreated mTNBC not candidate for a PDL1 inhibitor #ESMO25 @OncoAlert #OncoAlert And another @NEJM publication 💪🏼 @JavierCortesMD
1
11
25
TROPION BREAST-02 1st line TNBC PDL1- Dato-DXd vs TPC mPFS m vs m OS m vs m PFS and OS improved
0
2
6
PAULIEN: Halted for futility. Equiv to comparing Kn189 vs KN24 in high PDL1 (small study). Hardly any never smokers. Await PERSEE but this is an important addition #ESMO25
2
8
23
🔬 Jay Lee (@UCLAHealth) breaks down new #ImmunoDriver2 insights in metastatic #NSCLC: higher CD8 T-cell infiltration + #PDL1 expression = better OS, especially in tumors without drivers or with KRAS mutations 💡🧬 Watch the full discussion from #ESMO25:
0
0
0
#MaTOSLung @BiagioRicciutMD @DanaFarber presents one of the most challenging #lungcancer cases Stage IV KRASG12D STK11 PDL1 high w rapid progression 👉🏽highlighting the big area of need to find treatments for patients who have poor IO prognostic indicators
2
4
15
In ASCENT-03, Sacituzumab Govitecan improved median PFS vs chemotherapy in the 1st line setting of PDL1-ineligible metastatic TNBC. Of note: 🔹Patients with an early relapse (< 6 months) ineligible 🔹Cross-over to Sacituzumab Govitecan allowed 👏 #ESMO25
@OncoAlert
0
5
16
Retrospective real-world study of 448 "MSI/dMMR" colorectal cancer pts (51% WT RAS/BRAF, 22% RASmut, 27% BRAF V600E) 🟢 WT shows an inflamed TiME: favorable response to ICI. 🟡BRAF V600E ↑ TMB, ↑ PDL1, inflamed TiME: strong response to ICI & potential antimetabolite
0
12
42
PDL1-inhi.Predictor: a two-tiered machine learning framework for predicting and prioritizing PDL1 inhibitors #machinelearning #compchem
0
0
3
KN671 update; 5y OS/EFS presented ; PDL1 relationship remains something to consider in MDM decision making. #ESMO25
0
1
5
First-line therapy in patients with advanced triple-negative #PDL1- (or IO ineligible) will change after #ESMO25: great presentation by super @JavierCortesMD of the #ASCENT03 trial @myESMO @OncoAlert #sacituzumabGovitecan #bcsm
0
16
41
Squamous cell ca of the lung -Smears and cell block -Adequate material to do molecular testing NGS,PDL1,met,Her 2,AlkD5F #cytopath
2
14
49
HARMONi-6; n532; ivo-chemo vs CPI-chemo in SqCC; PFS interim analysis; PFS HR 0.60; almost doubles mPFS; HR consistent across all pdl1 strata #ESMO25
1
3
8